China Pharma Holdings, Inc.: Form 10-K for the period ended Dec 31, 2014
Filed with the SEC on Mar 30, 2015 and accepted by EDGAR at Mar 30, 2015, 16:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2014-01-01 to 2014-12-31 | $24.9m | us-gaap:Revenues |
| Cost of revenue | 12 months2014-01-01 to 2014-12-31 | $17.2m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2014-01-01 to 2014-12-31 | $5.5m | us-gaap:GrossProfit |
| Research and development | 12 months2014-01-01 to 2014-12-31 | $2.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2014-01-01 to 2014-12-31 | −$25.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2014-01-01 to 2014-12-31 | −$785.8k | us-gaap:InterestExpense |
| Income tax | 12 months2014-01-01 to 2014-12-31 | −$77.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2014-01-01 to 2014-12-31 | −$26.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2014-01-01 to 2014-12-31 | −$0.60 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2014-01-01 to 2014-12-31 | −$0.60 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2014-01-01 to 2014-12-31 | $4.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2014-01-01 to 2014-12-31 | −$5.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2014-12-31 | $5.3m | us-gaap:Cash |
| Current assets | At period end2014-12-31 | $54.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-12-31 | $132.1m | us-gaap:Assets |
| Current liabilities | At period end2014-12-31 | $14.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-12-31 | $25.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2014-12-31 | $106.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001010549-15-000090. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.